Comparison 3. High vs low LCn3 omega‐3 fats (tertiary outcomes).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Blood pressure, mmHg ‐ LCn3	15		Mean Difference (IV, Random, 95% CI)	Subtotals only
1.1 Systolic BP ‐ LCn3	15	34413	Mean Difference (IV, Random, 95% CI)	0.02 [‐0.32, 0.35]
1.2 Diastolic BP ‐ LCn3	14	35386	Mean Difference (IV, Random, 95% CI)	‐0.02 [‐0.22, 0.17]
2 Serious adverse events ‐ LCn3	14		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1 Any serious adverse events	1	402	Risk Ratio (M‐H, Random, 95% CI)	1.05 [0.78, 1.41]
2.2 Bleeding	8	45562	Risk Ratio (M‐H, Random, 95% CI)	1.06 [0.73, 1.52]
2.3 GI hospitalisation	1	200	Risk Ratio (M‐H, Random, 95% CI)	1.75 [0.53, 5.79]
2.4 Pulmonary embolus or DVT ‐ LCn3	4	3011	Risk Ratio (M‐H, Random, 95% CI)	1.25 [0.41, 3.78]
2.5 Progression to advanced AMD (age‐related macular degeneration)	1	4203	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.90, 1.02]
3 Side effects ‐ LCn3	33		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 Dropouts due to side effects	23	16755	Risk Ratio (M‐H, Random, 95% CI)	1.16 [0.99, 1.36]
3.2 Abdominal pain or discomfort	7	14650	Risk Ratio (M‐H, Random, 95% CI)	1.10 [0.84, 1.45]
3.3 Diarrhoea	10	2428	Risk Ratio (M‐H, Random, 95% CI)	1.15 [0.92, 1.43]
3.4 Nausea	5	1234	Risk Ratio (M‐H, Random, 95% CI)	1.73 [1.23, 2.44]
3.5 Any gastrointestinal side effect ‐ LCn3 fats	29	65185	Risk Ratio (M‐H, Random, 95% CI)	1.12 [0.94, 1.34]
3.6 Skin problems (itching, rashes)	8	36186	Risk Ratio (M‐H, Random, 95% CI)	1.04 [0.47, 2.30]
3.7 Headache or worsening migraine	3	991	Risk Ratio (M‐H, Random, 95% CI)	0.80 [0.48, 1.35]
3.8 Reflux	1	202	Risk Ratio (M‐H, Random, 95% CI)	1.42 [0.71, 2.81]
3.9 Pain (joint, lumbar, muscle pain)	1	18645	Risk Ratio (M‐H, Random, 95% CI)	0.80 [0.64, 0.99]
3.10 All side effects combined	13	38904	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.95, 1.08]
4 Dropouts ‐ LCn3	30	31321	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.95, 1.09]